{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:37:26Z","timestamp":1770907046185,"version":"3.50.1"},"reference-count":94,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Recent advances in melanoma therapy have significantly improved the prognosis of metastasized melanoma. However, large therapeutic gaps remain that need to be closed by new strategies. Antiapoptotic Bcl-2 proteins critically contribute to apoptosis deficiency and therapy resistance. They can be targeted by BH3 mimetics, small molecule antagonists that mimic the Bcl-2 homology domain 3 (BH3) of proapoptotic BH3-only proteins. By applying in vitro experiments, we aimed to obtain an overview of the possible suitability of BH3 mimetics for future melanoma therapy. Thus, we investigated the effects of ABT-737 and ABT-263, which target Bcl-2, Bcl-xL and Bcl-w as well as the Bcl-2-selective ABT-199 and the Mcl-1-selective S63845, in a panel of four BRAF-mutated and BRAF-WT melanoma cell lines. None of the inhibitors showed significant effectiveness when used alone; however, combination of S63845 with each one of the three ABTs almost completely abolished melanoma cell survival and induced apoptosis in up to 50\u201390% of the cells. Special emphasis was placed here on the understanding of the downstream pathways involved, which may allow improved applications of these strategies. Thus, cell death induction was correlated with caspase activation, loss of mitochondrial membrane potential, phosphorylation of histone H2AX, and ROS production. Caspase dependency was demonstrated by a caspase inhibitor, which blocked all effects. Upregulation of Mcl-1, induced by S63845 itself, as reported previously, was blocked by the combinations. Indeed, Mcl-1, as well as XIAP (X-linked inhibitor of apoptosis), were strongly downregulated by combination treatments. These findings demonstrate that melanoma cells can be efficiently targeted by BH3 mimetics, but the right combinations have to be selected. The observed pronounced activation of apoptosis pathways demonstrates the decisive role of apoptosis in the loss of cell viability by BH3 mimetics.<\/jats:p>","DOI":"10.3390\/ijms25063453","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T09:39:31Z","timestamp":1710841171000},"page":"3453","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2\/Bcl-xL\/Bcl-w Inhibitors"],"prefix":"10.3390","volume":"25","author":[{"given":"Zhe","family":"Peng","sequence":"first","affiliation":[{"name":"Skin Cancer Centre Charit\u00e9, Department of Dermatology and Allergy, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Charit\u00e9platz 1, 10117 Berlin, Germany"},{"name":"Clinical Medicine, University of South China, Hengyang 421001, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1815-2091","authenticated-orcid":false,"given":"Bernhard","family":"Gillissen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, and Tumor Immunology, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 13125 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Richter","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology, and Tumor Immunology, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, 13125 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3922-3327","authenticated-orcid":false,"given":"Tobias","family":"Sinnberg","sequence":"additional","affiliation":[{"name":"Skin Cancer Centre Charit\u00e9, Department of Dermatology and Allergy, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Charit\u00e9platz 1, 10117 Berlin, Germany"},{"name":"Division of Dermatooncology, Department of Dermatology, University of T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max S.","family":"Schlaak","sequence":"additional","affiliation":[{"name":"Skin Cancer Centre Charit\u00e9, Department of Dermatology and Allergy, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Charit\u00e9platz 1, 10117 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8533-1519","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Eberle","sequence":"additional","affiliation":[{"name":"Skin Cancer Centre Charit\u00e9, Department of Dermatology and Allergy, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Charit\u00e9platz 1, 10117 Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejca.2022.03.008","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune Checkpoint Blockade in Cancer Therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1016\/S1470-2045(14)70072-5","article-title":"Systemic treatment for BRAF-mutant melanoma: Where do we go next?","volume":"15","author":"Menzies","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment\u2014Update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/15384047.2015.1095401","article-title":"Interleukin-2, Ipilimumab, and Anti-PD-1: Clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma","volume":"22","author":"Hughes","year":"2021","journal-title":"Cancer Biol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11912-015-0485-6","article-title":"Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma","volume":"18","author":"Johnpulle","year":"2016","journal-title":"Curr. Oncol. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.annonc.2021.03.198","article-title":"Novel adjuvant options for cutaneous melanoma","volume":"32","author":"Dimitriou","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1365-2133.2007.07855.x","article-title":"Apoptosis pathways as promising targets for skin cancer therapy","volume":"156","author":"Eberle","year":"2007","journal-title":"Brit. J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nri2115","article-title":"Life and death in peripheral T cells","volume":"7","author":"Krammer","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/sj.cdd.4401160","article-title":"Many cuts to ruin: A comprehensive update of caspase substrates","volume":"10","author":"Fischer","year":"2003","journal-title":"Cell Death Differ."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1023\/A:1016119328968","article-title":"Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: An update","volume":"7","author":"Soldani","year":"2002","journal-title":"Apoptosis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9390","DOI":"10.1074\/jbc.275.13.9390","article-title":"Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139","volume":"275","author":"Rogakou","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.molcel.2006.05.023","article-title":"Cell apoptosis: Requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3","volume":"23","author":"Lu","year":"2006","journal-title":"Mol. Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: The balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/mc.22924","article-title":"Crucial role of reactive oxygen species (ROS) for the proapoptotic effects of indirubin derivative DKP-073 in melanoma cells","volume":"58","author":"Zhivkova","year":"2019","journal-title":"Mol. Carcinog."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e839","DOI":"10.1038\/cddis.2013.344","article-title":"ROS-dependent phosphorylation of Bax by wortmannin sensitizes melanoma cells for TRAIL-induced apoptosis","volume":"4","author":"Quast","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.molcel.2010.01.025","article-title":"The BCL-2 family reunion","volume":"37","author":"Chipuk","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.0022-202x.2001.01409.x","article-title":"The Bax\/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95\/Fas-mediated apoptosis","volume":"117","author":"Raisova","year":"2001","journal-title":"J. Investig. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nm0298-232","article-title":"bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice","volume":"4","author":"Jansen","year":"1998","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Eberle, J. (2019). Countering TRAIL Resistance in Melanoma. Cancers, 11.","DOI":"10.3390\/cancers11050656"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.V82.6.1820.1820","article-title":"bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia","volume":"82","author":"Hanada","year":"1993","journal-title":"Blood"},{"key":"ref_27","first-page":"5501","article-title":"Immunohistochemical analysis of in vivo patterns of Bcl-X expression","volume":"54","author":"Krajewski","year":"1994","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1073\/pnas.90.8.3516","article-title":"MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2","volume":"90","author":"Kozopas","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","article-title":"The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs","volume":"22","author":"Diepstraten","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s004030050479","article-title":"Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma","volume":"292","author":"Leiter","year":"2000","journal-title":"Arch. Dermatol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/jcp.20413","article-title":"Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth","volume":"205","author":"Trisciuoglio","year":"2005","journal-title":"J. Cell. Physiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41419-019-1568-3","article-title":"BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival","volume":"10","author":"Lee","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41419-020-2417-0","article-title":"BCL-w: Apoptotic and non-apoptotic role in health and disease","volume":"11","author":"Hartman","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1158\/0008-5472.CAN-19-1784","article-title":"Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAFV600E-Driven Melanoma","volume":"80","author":"Kim","year":"2020","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/mc.23253","article-title":"Mcl-1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells","volume":"59","author":"Sarif","year":"2020","journal-title":"Mol. Carcinog."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1038\/cddis.2010.18","article-title":"A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy","volume":"1","author":"Placzek","year":"2010","journal-title":"Cell Death Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2018.11.004","article-title":"BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines","volume":"34","author":"Merino","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Peng, Z., Gillissen, B., Richter, A., Sinnberg, T., Schlaak, M.S., and Eberle, J. (2023). Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054961"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Torrens-Mas, M., Cordani, M., Mullappilly, N., Pacchiana, R., Riganti, C., Palmieri, M., Pons, D.G., Roca, P., Oliver, J., and Donadelli, M. (2020). Mutant p53 induces SIRT3\/MnSOD axis to moderate ROS production in melanoma cells. Arch. Biochem. Biophys., 679.","DOI":"10.1016\/j.abb.2019.108219"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/1078-0432.CCR-22-2088","article-title":"Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies","volume":"29","author":"Tantawy","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7863","DOI":"10.1038\/sj.onc.1208069","article-title":"Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis","volume":"23","author":"Herrant","year":"2004","journal-title":"Oncogene"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","article-title":"BCL-2 protein family: Attractive targets for cancer therapy","volume":"28","author":"Kaloni","year":"2023","journal-title":"Apoptosis"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: A phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2007.01.037","article-title":"Programmed anuclear cell death delimits platelet life span","volume":"128","author":"Mason","year":"2007","journal-title":"Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","article-title":"Venetoclax: First Global Approval","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2159-8290.CD-18-1151","article-title":"A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer","volume":"9","author":"Lok","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1158\/1078-0432.CCR-17-1606","article-title":"Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression","volume":"24","author":"Lochmann","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.2217\/fon-2018-0121","article-title":"Accelerating drug development in pediatric cancer: A novel Phase I study design of venetoclax in relapsed\/refractory malignancies","volume":"14","author":"Place","year":"2018","journal-title":"Future Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Kehr, S., and Vogler, M. (2021). It\u2019s time to die: BH3 mimetics in solid tumors. Biochim. Biophys. Acta Mol. Cell Res., 1868.","DOI":"10.1016\/j.bbamcr.2021.118987"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41419-020-2646-2","article-title":"MCL1 inhibitors S63845\/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells","volume":"11","author":"Mukherjee","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/jid.2008.327","article-title":"BH3 Mimetic ABT-737 and a Proteasome Inhibitor Synergistically Kill Melanomas through Noxa-Dependent Apoptosis","volume":"129","author":"Miller","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature09779","article-title":"Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7","volume":"471","author":"Wertz","year":"2011","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1182\/blood-2018-06-859405","article-title":"Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use","volume":"132","author":"Brennan","year":"2018","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/1078-0432.CCR-18-0867","article-title":"NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263","volume":"25","author":"Dastur","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies","volume":"36","author":"Guieze","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"E1288","DOI":"10.1073\/pnas.1411848112","article-title":"Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer","volume":"112","author":"Faber","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1541-7786.MCR-16-0280-T","article-title":"Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2\/Bcl-xL Blockade","volume":"15","author":"Williams","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","article-title":"Targeting MCL-1 in cancer: Current status and perspectives","volume":"14","author":"Wang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1021\/acs.jmedchem.9b00134","article-title":"Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular Activity","volume":"62","author":"Szlavik","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41418-019-0486-3","article-title":"Saga of Mcl-1: Regulation from transcription to degradation","volume":"27","author":"Senichkin","year":"2020","journal-title":"Cell Death Differ."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1002\/ijc.33000","article-title":"Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma","volume":"147","author":"Tseng","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1038\/s41388-018-0268-2","article-title":"Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition","volume":"37","author":"Weeden","year":"2018","journal-title":"Oncogene"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.canlet.2020.02.041","article-title":"Targeting BCL-2 proteins in pediatric cancer: Dual inhibition of BCL-X(L) and MCL-1 leads to rapid induction of intrinsic apoptosis","volume":"482","author":"Kehr","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41419-020-02815-0","article-title":"Defining the susceptibility of colorectal cancers to BH3-mimetic compounds","volume":"11","author":"Luo","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Mukherjee, N., Amato, C.M., Skees, J., Todd, K.J., Lambert, K.A., Robinson, W.A., Van Gulick, R., Weight, R.M., Dart, C.R., and Tobin, R.P. (2020). Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. Cancers, 12.","DOI":"10.3390\/cancers12082182"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Griffioen, M.S., de Leeuw, D.C., Janssen, J., and Smit, L. (2022). Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies. Cancers, 14.","DOI":"10.3390\/cancers14143456"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s41416-020-0795-9","article-title":"A direct comparison of selective BH3-mimetics reveals BCL-X(L), BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma","volume":"122","author":"Bierbrauer","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2147\/CMAR.S265788","article-title":"Synergistic Effects of TW-37 and ABT-263 on Renal Cell Carcinoma Cells","volume":"13","author":"Yu","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41419-018-0932-z","article-title":"BH3 mimetics induce apoptosis independent of DRP-1 in melanoma","volume":"9","author":"Mukherjee","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.canlet.2020.11.036","article-title":"BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF(V600E) melanoma cells","volume":"499","author":"Hartman","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"40535","DOI":"10.18632\/oncotarget.5755","article-title":"Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1\/2 inhibitors in melanoma","volume":"6","author":"Fofaria","year":"2015","journal-title":"Oncotarget"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00204-021-02987-4","article-title":"The BH3 mimetic (\u00b1) gossypol induces ROS-independent apoptosis and mitochondrial dysfunction in human A375 melanoma cells in vitro","volume":"95","author":"Haasler","year":"2021","journal-title":"Arch. Toxicol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1593\/neo.09692","article-title":"Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax","volume":"11","author":"Jiang","year":"2009","journal-title":"Neoplasia"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1016\/j.bbamcr.2016.09.012","article-title":"Activation of apoptosis signalling pathways by reactive oxygen species","volume":"1863","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.bcp.2009.09.022","article-title":"New caspase-independent but ROS-dependent apoptosis pathways are targeted in melanoma cells by an iron-containing cytosine analogue","volume":"79","author":"Franke","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"11348","DOI":"10.1158\/0008-5472.CAN-06-1748","article-title":"A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species","volume":"66","author":"Verhaegen","year":"2006","journal-title":"Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00280-009-1001-1","article-title":"ABT-737, a BH3 mimetic, induces glutathione depletion and oxidative stress","volume":"65","author":"Howard","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"101313","DOI":"10.1016\/j.tranon.2021.101313","article-title":"Co-targeting MCL-1 and ERK1\/2 kinase induces mitochondrial apoptosis in rhabdomyosarcoma cells","volume":"16","author":"Winkler","year":"2022","journal-title":"Transl. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41375-018-0201-2","article-title":"The MCL1-specific inhibitor S63845 acts synergistically with venetoclax\/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells","volume":"33","author":"Li","year":"2019","journal-title":"Leukemia"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Alcon, C., Gomez Tejeda Zanudo, J., Albert, R., Wagle, N., Scaltriti, M., Letai, A., Samitier, J., and Montero, J. (2021). ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins. Cells, 10.","DOI":"10.3390\/cells10071659"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Keuling, A.M., Felton, K.E., Parker, A.A., Akbari, M., Andrew, S.E., and Tron, V.A. (2009). RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: Role for a caspase-8-dependent pathway. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0006651"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e2594","DOI":"10.1038\/cddis.2017.6","article-title":"Critical role of reactive oxygen species (ROS) for synergistic enhancement of apoptosis by vemurafenib and the potassium channel inhibitor TRAM-34 in melanoma cells","volume":"8","author":"Bauer","year":"2017","journal-title":"Cell Death Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e477","DOI":"10.1038\/cddis.2012.198","article-title":"Sensitization of melanoma cells for TRAIL-induced apoptosis by BMS-345541 correlates with altered phosphorylation and activation of Bax","volume":"4","author":"Berger","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0006-2952(03)00509-4","article-title":"The histone deacetylase inhibitor suberic bishydroxamate: A potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis","volume":"66","author":"Zhang","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/jnci\/51.5.1417","article-title":"In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors","volume":"51","author":"Giard","year":"1973","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ijc.2910410412","article-title":"Glycoprotein P3.58, associated with tumor progression in malignant melanoma, is a novel leukocyte activation antigen","volume":"41","author":"Holzmann","year":"1988","journal-title":"Int. J. Cancer"},{"key":"ref_92","first-page":"2902","article-title":"Cell-mediated cytotoxicity for bladder carcinoma: Evaluation of a workshop","volume":"35","author":"Bean","year":"1975","journal-title":"Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1073\/pnas.73.9.3278","article-title":"Cell surface antigens of human malignant melanoma: Mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells","volume":"73","author":"Carey","year":"1976","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/6\/3453\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:15:59Z","timestamp":1760105759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/6\/3453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":94,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["ijms25063453"],"URL":"https:\/\/doi.org\/10.3390\/ijms25063453","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,19]]}}}